Dr Nick Johnson appointed as Chief Strategy and Impact Officer of CGT Catapult
October 8, 2020Business Services
Dr Nick Johnson has been appointed the Chief Strategy and Impact Officer of the Cell and Gene Therapy Catapult. Johnson …
Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisations
October 8, 2020Manufacturing and Production Eli Lilly, FDA
Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.
34 reported coronavirus infections in White House-linked staff
October 8, 2020Medical Communications COVID, Trump, US, white house
The coronavirus outbreak that has infected notable figures of the Trump administration has spread to 34 White House Staffers and …
COVID-19 has caused over three times more deaths than flu or pneumonia in England and Wales
October 8, 2020Medical Communications, Research and Development COVID-19, UK, flu
Newly released data has revealed that COVID-19 has resulted in many more deaths than influenza or pneumonia in England and …
Regeneron applies for FDA Emergency Use Authorization for COVID-19 antibody treatment given to Trump
October 8, 2020Manufacturing and Production COVID, Trump, coronavirus
Regeneron has announced that it has applied for an Emergency Use Authorization from the FDA for its experimental antibody therapy …
Gilead to meet rising remdesivir demand in Europe with new supply deal
October 8, 2020Manufacturing and Production COVID-19, Europe, Gilead
The European Commission (EC) has signed a new joint procurement agreement (JPA) with pharma firm Gilead to improve access to …
GSK tells UK staff to turn off NHS COVID-19 tracking app while at work
October 7, 2020Research and Development COVID, GSK, covid app
GlaxoSmithKline has told its employees to turn off the new NHS coronavirus tracking app at work as it could be …
Johnson & Johnson to spend over $100m to settle 1,000 talc powder lawsuits
October 7, 2020Research and Development
Johnson & Johnson have agreed to pay over $100 million to settle more than 1,000 lawsuits that blame the company’s …
FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis
October 7, 2020Research and Development, Sales and Marketing Biogen, Glenmark, generic, multiple sclerosis
Glenmark Pharma will be celebrating after it secured FDA approval in the US to market dimethyl fumarate, a generic version …
EMA launches rolling regulatory review of Pfizer and BioNTech’s COVID-19 vaccine
October 7, 2020Research and Development, Sales and Marketing BioNTech, COVID-19, EMA, Pfizer, Vaccine
European Medicines Agency has launched a “rolling review” of the promising COVID-19 vaccine candidate BNT162b2 currently in development from BioNTech …
Pharmafile.com’s weekly COVID-19 news round-up
October 7, 2020Research and Development COVID, COVID-19, corornavirus
The coronavirus news this week focuses on treatments, with Enlivex Therapeutics releasing positive data for its therapy Allocetra as a …
Company veteran Belén Garijo named as Merck KGaA’s first-ever female CEO
October 6, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
German pharma firm Merck KGaA has taken the decision to appoint its first female Chief Executive Officer in its 352-year …
Aimovig reduces frequency of episodic migraines, five-year data reveals
October 6, 2020Manufacturing and Production, Research and Development Aimovig
Amgen and Novartis have revealed new five-year Phase 2 data during the Migraine Trust Virtual Symposium for their calcitonin gene-related …
NHS warns that UK could face drugs shortages after Brexit stockpile has been used to fight COVID-19
October 6, 2020Manufacturing and Production
The NHS has warned that hospitals could face shortages of drugs during the second wave of coronavirus due to the …
Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma
October 6, 2020Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo
Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …
White House halts release of new FDA standards for the Emergency Use Authorization of COVID-19 vaccine
October 6, 2020Manufacturing and Production FDA, Trump, Vaccine, coronavirus vaccines
The Trump White House is blocking new federal guidance for the emergency release of coronavirus vaccines that would essentially ensure …
Bristol Myers Squibb agrees $13 billion deal to acquire MyoKardia
October 6, 2020Manufacturing and Production BSM, FDA, MyoKardia
Bristol Myers Squibb (BMS) is to purchase MyoKardia for $13 billion to boost its heart disease treatments portfolio. The deal …
Alivio Therapeutics receives $3.3m from US Department of Defense to support development of IBD drug candidate
October 5, 2020Research and Development, Sales and Marketing Alivio, US, ibd, pharma
The US Department of Defense (DoD) has committed a Technology/Therapeutic Development Award to the value of $3.3 million to biotech …
ViiV’s two-drug regimen proves non-inferior in treatment-naive HIV-1
October 5, 2020Research and Development, Sales and Marketing HIV-1, ViiV Healthcare, pharma
ViiV Healthcare has taken the opportunity at the HIV Glasgow 2020 Virtual Congress to unveil three-year Phase 3 data from …
FDA defies advisory panel recommendation, rejecting Mesoblast’s Ryoncil in paediatric steroid-refractory acute graft versus host disease
October 5, 2020Sales and Marketing FDA, Mesoblast, Ryoncil
The FDA has issued a surprising rejection of Mesoblast’s Ryoncil (remestemcel-L) as a treatment for paediatric steroid-refractory acute graft versus …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
